Pharmaceutical News RSS Feed - Pharmaceutical News

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

Roskamp Institute Discovers New Target For Drugs To Treat Alzheimer's Disease

Scientists at the Roskamp Institute, a not-for-profit biomedical research facility specializing in Alzheimer's disease research, have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder. [More]
Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'. [More]
Life science investment in Northern England: an interview with Dr Geoff Davison, CEO, Bionow

Life science investment in Northern England: an interview with Dr Geoff Davison, CEO, Bionow

There are a number of challenges, but primarily, it's access to funding. The recent BioCap Conference focussed on the access small businesses have to funding and how that's driven by changes in the market place. [More]
PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand. [More]
EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month. [More]
Digoxin drug may be adaptable for ALS treatment, study suggests

Digoxin drug may be adaptable for ALS treatment, study suggests

Digoxin, a medication used in the treatment of heart failure, may be adaptable for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, paralyzing disease, suggests new research at Washington University School of Medicine in St. Louis. [More]
CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma Corp. today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited, the originator of tosedostat, and Chroma Therapeutics Ltd., through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America. [More]
Virginia Tech professor developing vaccine that could help smokers overcome nicotine addiction

Virginia Tech professor developing vaccine that could help smokers overcome nicotine addiction

A Virginia Tech professor is working on a vaccine that could help smokers conquer their nicotine addiction, making many smoking-related diseases and deaths relics of the 21st century. [More]
WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

WHO convened a meeting with high-ranking government representatives from Ebola-affected countries and development partners, civil society, regulatory agencies, vaccine manufacturers and funding agencies yesterday to discuss and agree on how to fast track testing and deployment of vaccines in sufficient numbers to impact the Ebola epidemic. [More]
Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”). [More]
Analgesics, anti-inflammatory drugs have beneficial effect on treatment of depression

Analgesics, anti-inflammatory drugs have beneficial effect on treatment of depression

Ordinary over the counter painkillers and anti-inflammatory drugs purchased from pharmacies may also be effective in the treatment of people suffering of depression. [More]
Novel way for treating non-cardiac chest pain due to esophageal hypersensitivity

Novel way for treating non-cardiac chest pain due to esophageal hypersensitivity

Chest pain doesn't necessarily come from the heart. An estimated 200,000 Americans each year experience non-cardiac chest pain, which in addition to pain can involve painful swallowing, discomfort and anxiety. Non-cardiac chest pain can be frightening for patients and result in visits to the emergency room because the painful symptoms, while often originating in the esophagus, can mimic a heart attack. [More]
Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience announces U.S. expansion with new translational oncology center

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced the opening of the Crown Bioscience US Research Center to be located at the David H. Murdock Research Institute (DHMRI), in Kannapolis, N.C. The new center, which will open in the 3rd quarter of 2014, represents significant U.S. market expansion for Crown. [More]

Beacon Hill Pharma opens second location in Wakefield, MA

Beacon Hill Pharma, Beacon Hill Staffing Group's pharma specialty division, opened a second location this past month just north of Boston in Wakefield, MA. This comes just one month after Beacon Hill [More]
Flu vaccines have protective effect against heart disease

Flu vaccines have protective effect against heart disease

Flu vaccines are known to have a protective effect against heart disease, reducing the risk of a heart attack. For the first time, this research, published in Vaccine, reveals the molecular mechanism that underpins this phenomenon. The scientists behind the study say it could be harnessed to prevent heart disease directly. [More]
Buprenorphine maintenance therapy better than detoxification for treating prescription opioid dependence

Buprenorphine maintenance therapy better than detoxification for treating prescription opioid dependence

For treating patients with prescription opioid dependence in primary care, buprenorphine maintenance therapy is superior to detoxification, according to a new study by Yale School of Medicine researchers published in the Oct. 20 issue of JAMA Internal Medicine. [More]
Obeticholic acid drug shows promise against bile acid diarrhoea

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms. [More]
CPS students and staff received EAIs for acute allergic reactions

CPS students and staff received EAIs for acute allergic reactions

During the 2012-2013 school year, 38 Chicago Public School (CPS) students and staff were given emergency medication for potentially life-threatening allergic reactions. [More]
Identifying infections rapidly: an interview with Dr. David J. Ecker

Identifying infections rapidly: an interview with Dr. David J. Ecker

Current methods for diagnosing infectious diseases are based on the 150-year-old culture method, where physicians collect a sample of a patient’s tissue, such as blood, mucus or urine, and transfer it onto media bottle to allow the pathogens to grow. [More]

reprintsWarehouse.com: A responsive platform launched by Springer Healthcare for pharmaceutical professionals

Springer Healthcare is proud to announce the launch of reprintsWarehouse.com – a responsive platform that enables pharmaceutical professionals to rapidly identify content that supports their product or device marketing activities, from a database of over 50,000 clinically relevant medical journals, books, continuing medical education materials and anatomical charts. [More]